Literature DB >> 26617684

Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Gerardo Botti1, Laura Marra1, Annamaria Anniciello1, Giosuè Scognamiglio1, Vincenzo Gigantino1, Monica Cantile1.   

Abstract

For specific subsets of melanocytic proliferations, there are morphologic limitations in the histological diagnosis, especially for borderline melanocytic tumors. In particular, Spitzoid proliferations can be difficult to diagnose. For these reasons, in the last years, clinic research has focused attention on discovery of new diagnostic markers. Published gene expression and proteomic profiling data indicate new candidate molecules involved in melanoma pathogenesis, and useful in differential diagnosis of difficult melanocytic lesions. Recently, the diagnostic power of galectin-3 was demonstrated in series of melanocytic lesions, with a strong increasing of expression in malignant lesions compared with benign lesions. Similarly, the accumulation of Collagen XVII antibody was detected in vertical melanoma fronts and associated with invasive phenotype. Moreover, overexpression of cyclin D1 and p21 was detected in Spitz nevi compared with non-spitzoid melanomas; Ki-67 appears highly expressed in deep areas of non-spitzoid melanomas. In this review, we overview of the main molecular markers that a useful tool for the differential diagnosis of benign, borderline and malignant melanocytic lesions, related to their biological behavior, useful also for predicting the evolution of the disease.

Entities:  

Keywords:  Benign and malignant melanocytic lesions; differential diagnosis; immunohistochemical markers

Mesh:

Substances:

Year:  2015        PMID: 26617684      PMCID: PMC4637769     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  71 in total

1.  Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.

Authors:  L Kanter-Lewensohn; M A Hedblad; J Wejde; O Larsson
Journal:  Mod Pathol       Date:  1997-09       Impact factor: 7.842

2.  Expression pattern of anti-apoptotic protein survivin in dysplastic nevi.

Authors:  M Adamkov; L Lauko; S Balentova; J Pec; M Pec; J Rajcani
Journal:  Neoplasma       Date:  2009       Impact factor: 2.575

Review 3.  Spitz naevus versus Spitzoid melanoma: when and how can they be distinguished?

Authors:  Kerry A Crotty; Richard A Scolyer; LingXiLawrence Li; A Allan Palmer; Lixiang Wang; Stanley W McCarthy
Journal:  Pathology       Date:  2002-02       Impact factor: 5.306

4.  BAX gene expression in melanoma metastases.

Authors:  A Gradilone; C Greco; P Gazzaniga; R Vercillo; M Napolitano; O Gandini; F Mattei; L Frati; A M Aglianò
Journal:  J Invest Dermatol       Date:  1996-02       Impact factor: 8.551

5.  p16 expression in primary malignant melanoma is associated with prognosis and lymph node status.

Authors:  Daniela Mihic-Probst; Christian D Mnich; Patrick A Oberholzer; Burkhardt Seifert; Bernd Sasse; Holger Moch; Reinhard Dummer
Journal:  Int J Cancer       Date:  2006-05-01       Impact factor: 7.396

6.  Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.

Authors:  Asmaa Gaber Abdou; Mostafa A Hammam; Shawky El Farargy; Azza G A Farag; Eman Nabil El Shafey; Sherine Farouk; Nada Farag Elnaidany
Journal:  Am J Dermatopathol       Date:  2010-12       Impact factor: 1.533

7.  Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.

Authors:  X C Mu; T A Tran; J S Ross; J A Carlson
Journal:  J Cutan Pathol       Date:  2000-05       Impact factor: 1.587

8.  Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression.

Authors:  A-C Goulet; Janine G Einsphar; David S Alberts; Anthony Beas; Cynthia Burk; Achyut Bhattacharyya; Jerry Bangert; Janet M Harmon; Hideji Fujiwara; Alane Koki; Mark A Nelson
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

9.  Expression of apoptosis regulators in cutaneous malignant melanoma.

Authors:  L Tang; V A Tron; J C Reed; K J Mah; M Krajewska; G Li; X Zhou; V C Ho; M J Trotter
Journal:  Clin Cancer Res       Date:  1998-08       Impact factor: 12.531

10.  Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.

Authors:  Y Wang; D Becker
Journal:  Oncogene       Date:  1996-03-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.